Akebia Therapeutics, Inc. Class Action Lawsuit - AKBA

Company
Akebia Therapeutics, Inc. (NASDAQ: AKBA)
Lead Plaintiff Deadline
May 13, 2022 (Expired)
Class Period
June 28, 2018 - September 2, 2020

Expired

Lead Plaintiff Deadline

May 13, 2022

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

(i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be eligible to join the AKBA class action lawsuit, you must have incurred a loss on shares of Akebia purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Akebia during the relevant time frame or pursuant to the relevant offering(s), you have until May 13, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP